CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro

Xenobiotica

Volumn 32, Issue 1, 2002, Pages 1-17

  Eaglings, V A ^a   Wiltshire, H ^b   Whitcombe, I W A ^b   Back, D J ^c  

^a IQVIA   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLITE; INDINAVIR; KETOCONAZOLE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG INHIBITION; FAST ATOM BOMBARDMENT MASS SPECTROMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IN VITRO STUDY; LIVER METABOLISM; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KETOCONAZOLE; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NELFINAVIR; RITONAVIR; SAQUINAVIR;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036150281     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250110085845     Document Type: Article

References (35)

1. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs
2. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9
3. In vitro approaches can predict human drug metabolism
4. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450
5. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A
6. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase
7. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions
8. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
9. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
10. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small intestinal cytochrome P450
11. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation
12. Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects
13. Selective inhibitors of cytochromes P450
14. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
15. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
16. Identification of rifampicin-inducible P4503A4 in human small bowel enterocytes
17. Cytochrome P450 mediated metabolism of the HIV-1 protease inhibitor Ritonavir (ABT-538) in human liver microsomes
18. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline
19. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
20. Molecular modelling of CYP3A4 from an alignment with CYP102: Identification of key interactions between putative active site residues and CYP3A-specific chemicals
21. Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical
22. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
23. Protein determination with the Folin phenol reagent
24. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
25. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV infected patients
26. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection
27. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection
28. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
29. Comparative studies of drug metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2-cells
30. Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man
31. Predicting the optimal dose of saquinavir via modelling of dose-exposure and exposure-effect relationships
32. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir
33. Human liver microsomal steroid metabolism. Identification of the major microsomal steroid 6β hydroxylase cytochrome P450 enzyme
34. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s
35. The synthesis of labelled forms of saquinavir